サマリー

欧州のG-CSF/PEG-G-CSF市場は、2023年から2030年にかけて5.1%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場セグメンテーションを行います：
欧州G-CSF/PEG-G-CSF市場、適応症別（好中球減少症、腫瘍、慢性・自己免疫疾患、血液疾患、成長調和不全、その他）、投与量（単剤、配合剤）、投与経路（静脈内、皮下）、パッケージ（シングルユースバイアル、プレフィルドシリンジ）、エンドユーザー（病院・クリニック、研究・学術機関、外来手術センター、その他）、流通チャネル（病院薬局、オンライン薬局、小売薬局、その他）、国（ドイツ、U．K.,フランス、イタリア、ロシア、オランダ、スペイン、スウェーデン、ポーランド、ベルギー、スイス、デンマーク、ノルウェー、フィンランド、トルコ、その他のヨーロッパ地域）産業動向と2030年までの予測

欧州のG-CSF/PEG-G-CSF市場の成長に寄与する主な要因として、以下のものが挙げられます：

- 血液がんやがん疾患の増加
- 発熱性好中球減少症の増加例
市場のプレーヤー：

欧州のG-CSF/PEG-G-CSF市場で事業を展開している主な市場関係者は以下の通りです：
- ルパン
- インタス・ファーマシューティカルズ・リミテッド（Intas Pharmaceuticals Ltd.
- バイオシダス
- STADA Arzneimittel AG
- USVプライベート・リミテッド
- ヴィアトリス社
- バイオコン
- フレゼニウス・カビAG
- アムジェン社
- ファイザー株式会社
- サンド・インターナショナル社
- カディラ・ファーマシューティカルズ
- ドクターレディーズラボラトリーズLtd.
- アムニール・ファーマシューティカルズLLC
- アコードヘルスケア
- インタス・ファーマシューティカルズ・リミテッド（Intas Pharmaceuticals Ltd.
- ムンディファーマ・インターナショナル
- テバ・ファーマシューティカル・インダストリーズ社
- 協和キリン(株)
- 江蘇亨瑞医薬有限公司

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 50
1.1 OBJECTIVES OF THE STUDY 50
1.2 MARKET DEFINITION 50
1.3 OVERVIEW OF EUROPE G-CSF / PEG-G-CSF MARKET 50
1.4 LIMITATIONS 52
1.5 MARKETS COVERED 52
2 MARKET SEGMENTATION 55
2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 CURRENCY AND PRICING 57
2.5 DBMR TRIPOD DATA VALIDATION MODEL 58
2.6 MULTIVARIATE MODELLING 61
2.7 TYPE LIFELINE CURVE 61
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
2.9 DBMR MARKET POSITION GRID 63
2.10 MARKET END USER COVERAGE GRID 64
2.11 VENDOR SHARE ANALYSIS 65
2.12 SECONDARY SOURCES 66
2.13 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 70
4.1 PESTEL ANALYSIS 71
4.2 PORTER’S FIVE FORCES 72
4.3 EUROPE G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 73
4.4 EUROPE G-CSF / PEG-G-CSF MARKET 74
4.5 STRATEGIES TO THE ENTER THE MARKET 74
4.5.1 JOINT VENTURE (PARTNERSHIPS): 74
4.5.2 ACQUISITION: 74
4.5.3 LINE EXPANSION VIA COLLABORATION: 74
4.5.4 PRODUCT APPROVAL: 75
4.5.5 PRODUCT LAUNCH: 75
4.5.6 GEOGRAPHIC EXPANSION: 75
4.5.7 COST LEADERSHIP: 76
4.5.8 PRODUCT DEVELOPMENT: 76
4.6 EUROPE G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 77
4.6.1 PATENT ANALYSIS 77
4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 78
4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 78
4.6.4 THERAPEUTIC ASSESSMENT 78
4.6.5 KEY PRICING STRATEGIES 79
4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 79
4.6.7 CONCLUSION 79
4.7 PIPELINE ANALYSIS FOR EUROPE G-CSF / PEG-G-CSF MARKET 80
5 EPIDEMIOLOGY 81
6 EUROPE G-CSF / PEG-G-CSF MARKET: REGULATIONS 84
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 89
7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 90
7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 91
7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 92
7.2 RESTRAIN 93
7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 93
7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 94
7.3 OPPORTUNITIES 95
7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 95
7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 95
7.4 CHALLENGES 96
7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 96
7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 96
8 EUROPE G-CSF/ PEG-G-CSF MARKET, BY INDICATION 97
8.1 OVERVIEW 98
8.2 NEUTROPENIA 102
8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 103
8.2.2 SEVERE CHRONIC NEUTROPENIA 103
8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 103
8.2.4 NEUTROPENIA IN HIV PATIENTS 103
8.2.5 CLOZAPINE INDUCED NEUTROPENIA 103
8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 103
8.2.7 CONGENITAL NEUTROPENIA 103
8.3 ONCOLOGY 104
8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 104
8.3.2 OTHERS 105
8.4 CHRONIC AND AUTO IMMUNE DISEASES 105
8.5 BLOOD DISORDERS 105
8.6 GROWTH HORMONE DEFICIENCY 106
8.7 OTHERS 107
9 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 108
9.1 OVERVIEW 109
9.2 MONO 112
9.3 COMBINATION 113
10 EUROPE G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 114
10.1 OVERVIEW 115
10.2 SUBCUTANEOUS 118
10.3 INTRAVENOUS 119
11 EUROPE G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 120
11.1 OVERVIEW 121
11.2 PRE FILLED SYRINGES 124
11.3 SINGLE USE VIALS 125
12 EUROPE G-CSF/ PEG-G-CSF MARKET, BY END USER 126
12.1 OVERVIEW 127
12.2 HOSPITALS AND CLINICS 130
12.3 RESEARCH & ACADEMIC INSTITUTES 130
12.4 AMBULATORY SURGICAL CENTERS 131
12.5 OTHERS 132
13 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 133
13.1 OVERVIEW 134
13.2 HOSPITALS PHARMACY 137
13.3 RETAIL PHARMACY 137
13.4 ONLINE PHARMACY 138
13.5 OTHERS 139
14 EUROPE G-CSF/PEG-G-CSF MARKET, BY REGION 140
14.1 EUROPE 141
14.1.1 RUSSIA 148
14.1.2 TURKEY 156
15 EUROPE G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 167
15.1 COMPANY SHARE ANALYSIS: EUROPE 167
16 SWOT ANALYSIS 168
17 COMPANY PROFILE 169
17.1 PFIZER INC. 169
17.1.1 COMPANY SNAPSHOT 169
17.1.2 REVENUE ANALYSIS 170
17.1.3 COMPANY SHARE ANALYSIS 170
17.1.4 PRODUCT PORTFOLIO 171
17.1.5 RECENT DEVELOPMENTS 171
17.2 VIATRIS INC. 172
17.2.1 COMPANY SNAPSHOT 172
17.2.2 REVENUE ANALYSIS 172
17.2.3 COMPANY SHARE ANALYSIS 173
17.2.4 PRODUCT PORTFOLIO 173
17.2.5 RECENT DEVELOPMENT 173
17.3 AMGEN INC. 174
17.3.1 COMPANY SNAPSHOT 174
17.3.2 REVENUE ANALYSIS 174
17.3.3 COMPANY SHARE ANALYSIS 175
17.3.4 PRODUCT PORTFOLIO 175
17.3.5 RECENT DEVELOPMENTS 175
17.4 STADA ARZENEIMITTEL AG 177
17.4.1 COMPANY SNAPSHOT 177
17.4.2 COMPANY SHARE ANALYSIS 177
17.4.3 PRODUCT PORTFOLIO 178
17.4.4 RECENT DEVELOPMENT 178
17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 179
17.5.1 COMPANY SNAPSHOT 179
17.5.2 REVENUE ANALYSIS 179
17.5.3 COMPANY SHARE ANALYSIS 180
17.5.4 PRODUCT PORTFOLIO 180
17.5.5 RECENT DEVELOPMENTS 180
17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 181
17.6.1 COMPANY SNAPSHOT 181
17.6.2 PRODUCT PORTFOLIO 181
17.6.3 RECENT DEVELOPMENTS 181
17.7 ACCORD HEALTHCARE 182
17.7.1 COMPANY SNAPSHOT 182
17.7.2 PRODUCT PORTFOLIO 182
17.7.3 RECENT DEVELOPMENTS 182
17.8 AMNEAL PHARMACEUTICALS LLC. 183
17.8.1 COMPANY SNAPSHOT 183
17.8.2 REVENUE ANALYSIS 183
17.8.3 PRODUCT PORTFOLIO 184
17.8.4 RECENT DEVELOPMENTS 184
17.9 APOTEX INC. 185
17.9.1 COMPANY SNAPSHOT 185
17.9.2 PRODUCT PORTFOLIO 185
17.9.3 RECENT DEVELOPMENT 185
17.10 BIOCON 186
17.10.1 COMPANY SNAPSHOT 186
17.10.2 REVENUE ANALYSIS 186
17.10.3 PRODUCT PORTFOLIO 187
17.10.4 RECENT DEVELOPMENT 187
17.11 BIO SIDUS 188
17.11.1 COMPANY SNAPSHOT 188
17.11.2 PRODUCT PORTFOLIO 188
17.11.3 RECENT DEVELOPMENTS 188
17.12 CADILA PHARMACEUTICALS 189
17.12.1 COMPANY SNAPSHOT 189
17.12.2 PRODUCT PORTFOLIO 189
17.12.3 RECENT DEVELOPMENTS 189
17.13 COHERUS BIOSCIENCES 190
17.13.1 COMPANY SNAPSHOT 190
17.13.2 REVENUE ANALYSIS 190
17.13.3 PRODUCT PORTFOLIO 191
17.13.4 RECENT DEVELOPMENT 191
17.14 DR. REDDY’S LABORATORIES LTD 192
17.14.1 COMPANY SNAPSHOT 192
17.14.2 REVENUE ANALYSIS 192
17.14.3 PRODUCT PORTFOLIO 193
17.14.4 RECENT DEVELOPMENTS 193
17.15 FRESENIUS KABI AG 194
17.15.1 COMPANY SNAPSHOT 194
17.15.2 PRODUCT PORTFOLIO 194
17.15.3 RECENT DEVELOPMENT 194
17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 195
17.16.1 COMPANY SNAPSHOT 195
17.16.2 PRODUCT PORTFOLIO 195
17.16.3 RECENT DEVELOPMENTS 195
17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 196
17.17.1 COMPANY SNAPSHOT 196
17.17.2 PRODUCT PORTFOLIO 196
17.17.3 RECENT DEVELOPMENTS 196
17.18 INTAS PHARMACEUTICALS LTD. 197
17.18.1 COMPANY SNAPSHOT 197
17.18.2 PRODUCT PORTFOLIO 197
17.18.3 RECENT DEVELOPMENT 197
17.19 KASHIV BIOSCIENCES, LLC. 198
17.19.1 COMPANY SNAPSHOT 198
17.19.2 PRODUCT PORTFOLIO 198
17.19.3 RECENT DEVELOPMENT 198
17.20 KYOWA KIRIN CO., LTD. 199
17.20.1 COMPANY SNAPSHOT 199
17.20.2 REVENUE ANALYSIS 199
17.20.3 PRODUCT PORTFOLIO 200
17.20.4 RECENT DEVELOPMENT 200
17.21 LUPIN 201
17.21.1 COMPANY SNAPSHOT 201
17.21.2 REVENUE ANALYSIS 201
17.21.3 PRODUCT PORTFOLIO 202
17.21.4 RECENT DEVELOPMENT 202
17.22 MUNDIPHARMA INTERNATIONAL. 203
17.22.1 COMPANY SNAPSHOT 203
17.22.2 PRODUCT PORTFOLIO 203
17.22.3 RECENT DEVELOPMENT 203
17.23 NAPP PHARMACEUTICALS LIMITED 204
17.23.1 COMPANY SNAPSHOT 204
17.23.2 PRODUCT PORTFOLIO 204
17.23.3 RECENT DEVELOPMENT 204
17.24 RELIANCE LIFE SCIENCES 205
17.24.1 COMPANY SNAPSHOT 205
17.24.2 PRODUCT PORTFOLIO 205
17.24.3 RECENT DEVELOPMENTS 205
17.25 SANDOZ INTERNATIONAL GMBH 206
17.25.1 COMPANY SNAPSHOT 206
17.25.2 REVENUE ANALYSIS 206
17.25.3 PRODUCT PORTFOLIO 207
17.25.4 RECENT DEVELOPMENTS 207
17.26 SPECTRUM PHARMACEUTICALS, INC. 208
17.26.1 COMPANY SNAPSHOT 208
17.26.2 PRODUCT PORTFOLIO 208
17.26.3 RECENT DEVELOPMENT 208
17.27 USV PRIVATE LIMITED 209
17.27.1 COMPANY SNAPSHOT 209
17.27.2 PRODUCT PORTFOLIO 209
17.27.3 RECENT DEVELOPMENTS 209
18 QUESTIONNAIRE 210
19 RELATED REPORTS 213

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET: 52
TABLE 2 EUROPE G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 69
TABLE 3 EUROPE NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 70
TABLE 4 EUROPE NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 70
TABLE 5 EUROPE ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 72
TABLE 6 EUROPE ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 72
TABLE 7 EUROPE CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 73
TABLE 8 EUROPE BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 74
TABLE 9 EUROPE GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 74
TABLE 10 EUROPE OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 75
TABLE 11 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION) 79
TABLE 12 EUROPE MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 13 EUROPE COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 14 EUROPE G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 85
TABLE 15 EUROPE SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 86
TABLE 16 EUROPE INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 17 EUROPE G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION) 91
TABLE 18 EUROPE PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 92
TABLE 19 EUROPE SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 93
TABLE 20 EUROPE G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION) 97
TABLE 21 EUROPE HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 98
TABLE 22 EUROPE RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 99
TABLE 23 EUROPE AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 99
TABLE 24 EUROPE OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 100
TABLE 25 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 104
TABLE 26 EUROPE HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 105
TABLE 27 EUROPE RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 106
TABLE 28 EUROPE ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 106
TABLE 29 EUROPE OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 107
TABLE 30 EUROPE G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 112
TABLE 31 EUROPE G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION) 112
TABLE 32 EUROPE G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 113
TABLE 33 EUROPE NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 113
TABLE 34 EUROPE ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 113
TABLE 35 EUROPE G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 114
TABLE 36 EUROPE G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 114
TABLE 37 EUROPE G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 114
TABLE 38 EUROPE G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 114
TABLE 39 EUROPE G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 115
TABLE 40 RUSSIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 116
TABLE 41 RUSSIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 116
TABLE 42 RUSSIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 117
TABLE 43 RUSSIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 117
TABLE 44 RUSSIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 117
TABLE 45 RUSSIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 117
TABLE 46 RUSSIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 117
TABLE 47 RUSSIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 118
TABLE 48 RUSSIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 118
TABLE 49 RUSSIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 118
TABLE 50 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 118
TABLE 51 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 119
TABLE 52 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 119
TABLE 53 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 119
TABLE 54 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 119
TABLE 55 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 120
TABLE 56 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 120
TABLE 57 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 120
TABLE 58 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 120
TABLE 59 RUSSIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 121
TABLE 60 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 121
TABLE 61 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 121
TABLE 62 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 121
TABLE 63 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 122
TABLE 64 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 122
TABLE 65 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 122
TABLE 66 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 122
TABLE 67 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 123
TABLE 68 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 123
TABLE 69 TURKEY G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 124
TABLE 70 TURKEY NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 124
TABLE 71 TURKEY ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 125
TABLE 72 TURKEY G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 125
TABLE 73 TURKEY MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125
TABLE 74 TURKEY G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 125
TABLE 75 TURKEY SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126
TABLE 76 TURKEY INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126
TABLE 77 TURKEY G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 126
TABLE 78 TURKEY PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127
TABLE 79 TURKEY SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127
TABLE 80 TURKEY G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 127
TABLE 81 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 128
TABLE 82 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 128
TABLE 83 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 128
TABLE 84 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 129
TABLE 85 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 129
TABLE 86 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 129
TABLE 87 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 130
TABLE 88 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 130
TABLE 89 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 130
TABLE 90 TURKEY G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 131
TABLE 91 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 131
TABLE 92 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 131
TABLE 93 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 132
TABLE 94 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132
TABLE 95 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 132
TABLE 96 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 133
TABLE 97 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133
TABLE 98 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 133
TABLE 99 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134